Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108849 · ClinicalTrials.gov registry record · Phase 3
Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 309
- Enrollment target
NCT00108849 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 309 participants.
The verdict
NCT00108849, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 309 participants
- Enrollment target
Study Summary
This trial is conducted in North America. The purpose of this study is to determine if Vagifem Low Dose is an effective and safe treatment for patients suffering from postmenopausal atrophic vaginitis.
Interventions
- DRUG estradiol, 10 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108849
The ClinicalTrials.gov registry entry for NCT00108849 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which estradiol, 10 mcg is the first listed.
NCT00108849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108849 about?
NCT00108849 is a clinical study titled "Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms". This trial is conducted in North America. The purpose of this study is to determine if Vagifem Low Dose is an effective and safe treatment for patients suffering from postmenopausal atrophic vaginitis.
What is the current status of trial NCT00108849?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 309 participants. The study started on 2005-03. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00108849?
The interventions under investigation include: estradiol, 10 mcg (DRUG).
Who is sponsoring clinical trial NCT00108849?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.